<DOC>
	<DOCNO>NCT00909779</DOCNO>
	<brief_summary>This multi-center study evaluate long-term safety arformoterol 15 mcg twice daily ( BID ) treatment subject moderate-to-severe COPD . Study participation consist total 6 visit approximately 1 year .</brief_summary>
	<brief_title>Safety Study Arformoterol Tartrate Inhalation Solution Chronic Obstructive Pulmonary Disease ( COPD ) Subjects</brief_title>
	<detailed_description>This multi-center , double-blind , randomize , placebo-controlled , parallel-group , outpatient , safety study evaluate long-term safety arformoterol 15 mcg twice daily ( BID ) treatment subject moderate-to-severe COPD . The administration arformoterol subject moderate severe COPD result meaningfully great incidence respiratory death COPD exacerbation -related hospitalization compare placebo ( nebulized saline non-long-acting beta2-agonist [ LABA ] COPD standard care treatment ) . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Subject must give write informed consent , include privacy authorization well adherence concomitant medication withhold period , prior participation . Females consider childbearing potential must surgically sterile ( total hysterectomy , bilateral salpingo oophorectomy , tubal ligation ) postmenopausal , define complete cessation menstruation least 1 year . Male female subject must least 40 year old time consent . Subjects must preestablished , document primary clinical diagnosis nonasthmatic COPD refer diagnosis nonasthmatic COPD . Subjects must baseline FEV1 ≤50 % predict volume Visits 1 2 ( predose ) . Subjects must FEV1 &gt; 0.50 L either Visit 1 2 ( predose ) . Subject 's respiratory status must clinically stable . Subjects must FEV1/forced vital capacity ( FVC ) ratio ≤70 % either Visit 1 2 ( predose ) . Subjects must least 1 COPD exacerbation within last year ( defined initiation increase dose oral steroid antibiotic treatment COPD ) . Subjects must ≥15 packyear smoke history baseline breathlessness severity grade ≥2 ( Modified Medical Research Council [ MMRC ] Dyspnea Scale Score ) Visit 2 . Female subject ≤65 year age must negative serum pregnancy test conduct Visit 1 prior randomization . Females childbearing potential must use acceptable method birth control . Subjects ' overall health must sufficiently stable complete study requirement base screen physical examination ( defined absence clinically relevant abnormality ) , medical history , 12lead ECG , clinical laboratory value ( hematology , serum chemistry urinalysis ) , vital sign ( heart rate , respiratory rate , blood pressure ) conduct within 30 day Visit 2 ( randomization ) . If hematology , chemistry , urinalysis result within laboratory 's reference range , subject include investigator judge deviation clinically significant . Subjects must minimum blood pressure 105/60 mmHg minimum rest pulse 50 bpm Screening Visit 1 . Subjects meet criterion Screening Visit 1 must meet criterion first day dose ( Day 1 ) order eligible study . Subjects medical condition cause low blood pressure low heart rate , , opinion Principal Investigator designee medical condition could resolve , may rescreened condition resolve . Subjects must willing able complete study questionnaire log reliably . Subjects must willing able comply study procedure visit schedule . Subjects must sufficient understanding English complete questionnaire log . Female subject pregnant lactating . Subjects history asthma , exception asthma diagnose childhood . Subjects blood eosinophil count &gt; 5 % total white blood cell count . Subjects febrile illness within 3 day Screening . Subjects malignant neoplasm non melanomatous basal cell skin cancer . Subjects history malignancy cancer free 5 year may enrol . Subjects currently use disallow medication unable complete medication washout period . Subjects take prohibited concurrent medication require washout &gt; 30 day may rescreened washout prohibited concurrent medication meet . Subjects life threatening/unstable respiratory status , include upper low respiratory tract infection , within previous 30 day prior screen . Subjects change dose type medication COPD within 2 week prior screen visit . Subjects stable dose COPD medication may rescreened stable dose least 14 day Subjects chest x ray take ≤3 month prior screen suggests diagnosis COPD ( eg , diagnostic pneumonia , infection , atelectasis , pneumothorax active/ongoing pulmonary condition ) . If chest x ray take ≤3 month prior screen , recent result unavailable review , chest x ray must perform prior visit 2 . Subjects medical condition cause abnormal finding , , opinion Principal Investigator designee medical condition could resolve , may rescreened condition resolve Subjects positive urine drug test screening . Subjects know history alcohol abuse may enrol study subject 's current alcohol use exceed 3 alcoholic beverage per day . Subjects whose schedule travel prevents completion require visit . Subjects schedule inpatient hospitalization elective surgery ( inpatient outpatient ) trial . Subjects may rescreened condition resolve . Subjects participate investigational drug study and/or COPD interventional trial within 30 day prior screen currently participate another investigational drug study COPD interventional trial . Subjects history allergic reaction study medication component study medication . Subjects study site staff member relatives study site staff member directly involve study . Subjects clinically significant cardiac , ( Functional Class III IV ; Objective Class C D New York Heart Association [ NYHA ] Functional Classification ) , hepatic , renal , gastrointestinal , endocrine , metabolic , neurologic , psychiatric disorder may interfere successful completion protocol .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Chronic obstructive pulmonary disease ( COPD )</keyword>
	<keyword>respiratory</keyword>
	<keyword>long-acting beta agonist ( LABA )</keyword>
</DOC>